Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 309


SRC signaling is crucial in the growth of synovial sarcoma cells.

Michels S, Trautmann M, Sievers E, Kindler D, Huss S, Renner M, Friedrichs N, Kirfel J, Steiner S, Endl E, Wurst P, Heukamp L, Penzel R, Larsson O, Kawai A, Tanaka S, Sonobe H, Schirmacher P, Mechtersheimer G, Wardelmann E, Büttner R, Hartmann W.

Cancer Res. 2013 Apr 15;73(8):2518-28. doi: 10.1158/0008-5472.CAN-12-3023. Epub 2013 Apr 11.


Insulin-like growth factor-1 receptor acts as a growth regulator in synovial sarcoma.

Friedrichs N, Küchler J, Endl E, Koch A, Czerwitzki J, Wurst P, Metzger D, Schulte JH, Holst MI, Heukamp LC, Larsson O, Tanaka S, Kawai A, Wardelmann E, Buettner R, Pietsch T, Hartmann W.

J Pathol. 2008 Dec;216(4):428-39. doi: 10.1002/path.2438.


Adaptor protein Crk induces Src-dependent activation of p38 MAPK in regulation of synovial sarcoma cell proliferation.

Watanabe T, Tsuda M, Tanaka S, Ohba Y, Kawaguchi H, Majima T, Sawa H, Minami A.

Mol Cancer Res. 2009 Sep;7(9):1582-92. doi: 10.1158/1541-7786.MCR-09-0064. Epub 2009 Sep 8.


Dasatinib inhibits migration and invasion in diverse human sarcoma cell lines and induces apoptosis in bone sarcoma cells dependent on SRC kinase for survival.

Shor AC, Keschman EA, Lee FY, Muro-Cacho C, Letson GD, Trent JC, Pledger WJ, Jove R.

Cancer Res. 2007 Mar 15;67(6):2800-8.


Inhibition of cell growth and up-regulation of MAD2 in human oesophageal squamous cell carcinoma after treatment with the Src/Abl inhibitor dasatinib.

Wang L, Guo B, Wang R, Jiang Y, Qin S, Liang S, Zhao Y, Guo W, Li K, Fan X.

Clin Sci (Lond). 2012 Jan;122(1):13-24. doi: 10.1042/CS20110230.


SS18-SSX fusion protein-induced Wnt/β-catenin signaling is a therapeutic target in synovial sarcoma.

Trautmann M, Sievers E, Aretz S, Kindler D, Michels S, Friedrichs N, Renner M, Kirfel J, Steiner S, Huss S, Koch A, Penzel R, Larsson O, Kawai A, Tanaka S, Sonobe H, Waha A, Schirmacher P, Mechtersheimer G, Wardelmann E, Büttner R, Hartmann W.

Oncogene. 2014 Oct 16;33(42):5006-16. doi: 10.1038/onc.2013.443. Epub 2013 Oct 28.


Disruption of fibroblast growth factor signal pathway inhibits the growth of synovial sarcomas: potential application of signal inhibitors to molecular target therapy.

Ishibe T, Nakayama T, Okamoto T, Aoyama T, Nishijo K, Shibata KR, Shima Y, Nagayama S, Katagiri T, Nakamura Y, Nakamura T, Toguchida J.

Clin Cancer Res. 2005 Apr 1;11(7):2702-12.


Inhibition of Src phosphorylation alters metastatic potential of osteosarcoma in vitro but not in vivo.

Hingorani P, Zhang W, Gorlick R, Kolb EA.

Clin Cancer Res. 2009 May 15;15(10):3416-22. doi: 10.1158/1078-0432.CCR-08-1657. Epub 2009 May 15.


Degradation of epidermal growth factor receptor mediates dasatinib-induced apoptosis in head and neck squamous cell carcinoma cells.

Lin YC, Wu MH, Wei TT, Chuang SH, Chen KF, Cheng AL, Chen CC.

Neoplasia. 2012 Jun;14(6):463-75.


Loss of SS18-SSX1 inhibits viability and induces apoptosis in synovial sarcoma.

Carmody Soni EE, Schlottman S, Erkizan HV, Uren A, Toretsky JA.

Clin Orthop Relat Res. 2014 Mar;472(3):874-82. doi: 10.1007/s11999-013-3065-9.


Synergistic antitumor effects of dasatinib and oxaliplatin in gastric cancer cells.

Shi M, Lou B, Ji J, Shi H, Zhou C, Yu Y, Liu B, Zhu Z, Zhang J.

Cancer Chemother Pharmacol. 2013 Jul;72(1):35-44. doi: 10.1007/s00280-013-2166-1. Epub 2013 May 28.


Identification and validation of phospho-SRC, a novel and potential pharmacodynamic biomarker for dasatinib (SPRYCEL), a multi-targeted kinase inhibitor.

Luo FR, Barrett YC, Yang Z, Camuso A, McGlinchey K, Wen ML, Smykla R, Fager K, Wild R, Palme H, Galbraith S, Blackwood-Chirchir A, Lee FY.

Cancer Chemother Pharmacol. 2008 Nov;62(6):1065-74. doi: 10.1007/s00280-008-0699-5. Epub 2008 Feb 27.


PH006, a novel and selective Src kinase inhibitor, suppresses human breast cancer growth and metastasis in vitro and in vivo.

Ma JG, Huang H, Chen SM, Chen Y, Xin XL, Lin LP, Ding J, Liu H, Meng LH.

Breast Cancer Res Treat. 2011 Nov;130(1):85-96. doi: 10.1007/s10549-010-1302-4. Epub 2010 Dec 22.


Dasatinib is preclinically active against Src-overexpressing human transitional cell carcinoma of the urothelium with activated Src signaling.

Levitt JM, Yamashita H, Jian W, Lerner SP, Sonpavde G.

Mol Cancer Ther. 2010 May;9(5):1128-35. doi: 10.1158/1535-7163.MCT-10-0096. Epub 2010 Apr 20.


Combined Inhibition of IGF-1R/IR and Src family kinases enhances antitumor effects in prostate cancer by decreasing activated survival pathways.

Dayyani F, Parikh NU, Varkaris AS, Song JH, Moorthy S, Chatterji T, Maity SN, Wolfe AR, Carboni JM, Gottardis MM, Logothetis CJ, Gallick GE.

PLoS One. 2012;7(12):e51189. doi: 10.1371/journal.pone.0051189. Epub 2012 Dec 26.


Identification of potential biomarkers for measuring inhibition of Src kinase activity in colon cancer cells following treatment with dasatinib.

Serrels A, Macpherson IR, Evans TR, Lee FY, Clark EA, Sansom OJ, Ashton GH, Frame MC, Brunton VG.

Mol Cancer Ther. 2006 Dec;5(12):3014-22. Epub 2006 Dec 5.


Inhibition of Src impairs the growth of met-addicted gastric tumors.

Bertotti A, Bracco C, Girolami F, Torti D, Gastaldi S, Galimi F, Medico E, Elvin P, Comoglio PM, Trusolino L.

Clin Cancer Res. 2010 Aug 1;16(15):3933-43. doi: 10.1158/1078-0432.CCR-10-0106. Epub 2010 Jul 13.

Supplemental Content

Support Center